Compare iShares Russell 2000 ETF (IWM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Novo Nordisk A/S — how do they compare? iShares Russell 2000 ETF trades at $278.92 (market cap $77.70B), while Novo Nordisk A/S trades at $38.39 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.1× iShares Russell 2000 ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Novo Nordisk A/S for 116 Days on average.
| IWM | NVO | |
|---|---|---|
Market Cap | $77.70B | $165.31B |
Volume | 35,598,983 | 11,432,838 |
52-Week High | $305.06 | $63.98 |
52-Week Low | $229.13 | $35.29 |
Typical Hold Time | 83 Days | 116 Days |
Sector | — | Health |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $278.05, up 0.12% with bearish technical signals from moving averages. The small-cap ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure evident from Envestnet's 4.6% stake reduction in Q3 2026.
Small-cap exposure offers diversification but faces near-term pressure from tightening financial conditions. The ETF's broad Russell 2000 composition includes unprofitable companies, creating performance drag. Upside potential exists if economic conditions improve, but current momentum favors large-caps amid rising interest rates and energy price volatility.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
